ESTEVE CO-LEADS INTERNATIONAL CONSORTIUM FOR THE DEVELOPMENT OF MORE EFFICACIOUS THERAPIES FOR NEUROPATHIC PAIN
NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. ESTEVE, along with five other partners, is part of this project for the development of novel, more efficacious treatments for chronic pain of neuropathic origin.
Neuropathic pain affects 8.2% of the population and the efficacy of current treatments is limited, which results in 60% of patients being improperly treated. NGN-PET is a 6-partner consortium led by ESTEVE, supported by Grünenthal and coordinated by Axxam, that brings together experts from industry, SMEs and academia and that will focus on the study of neuronal and glial cells to discover novel, more efficacious treatments for neuropathic pain.
Specifically, the new approach of NGN-PET will investigate neuron-glial interactions in two models of neuropathic pain -induced by chemotherapy or trauma- to develop cellular systems that provide a translational platform and create human-predictive test systems that can be implemented in the drug discovery process.
With a duration of 3 years, the NGN-PET project is supported by over 3 million euros from IMI2 and industry partners in direct and in-kind contributions
Download the complete news in pdf
ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE
Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europeread more
POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN
The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugsread more
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more